Clinical Perspectives

large-target

A Disease Overview

slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide
slide

References

Lorem ipsum dolor sit amet, consectetur adipisicing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Presentation Description

Systemic mastocytosis is a rare, clonal mast cell neoplasm driven by the KIT D816V mutation in ~95% of patients1-4. In patients with systemic mastocytosis, abnormal mast cell activation and uncontrolled mast cell proliferation result in unpredictable, debilitating symptoms1-4.

This module is intended to increase awareness of systemic mastocytosis among health care professionals to prevent delays in diagnosis. It includes information about diagnosis and pathogenesis of systemic mastocytosis and provides an overview of the patient experience and treatment options.

References: 1. Vaes M et al. Front Med. 2017;4:110. 2. Jara-Acevedo M et al. Mod Pathol. 2015;28(8):1138-1149. 3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372. 4. Jennings SV et al. Immunol Allergy Clin North Am. 2018;38(3):505-525.

poly-lines-bg

Blueprint Medicines and associated logos are trademarks of Blueprint Medicines Corporation.
© 2021 Blueprint Medicines Corporation.
07/2021 USBP-PRSM-20.001.2